A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name Ozempic — may help reduce not only alcohol cravings, but the amount of alcohol consumed when someone on the drug does drink

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink less alcohol.

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really does help curb drinking

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol cravings and consumption.